Join hosts Chad Mulvany and Shawn Stack as they share the latest healthcare policy and legislative updates for the week of June 24, 2026. First, they discuss the Health Resources and Services Administration’s (HRSA) efforts to implement a new 340B rebate model after a previous attempt faced legal setbacks. They also explore a new analysis of the financial impact of the One Big Beautiful Bill Act on healthcare providers and strategies to help organizations prepare. Later in the episode, they’re joined by Victoria Duffel from the Healthcare Consulting practice at Forvis Mazars to discuss the Trump administration’s emphasis on price transparency enforcement, including recent messages to hospitals from CMS and the Department of Health and Human Services (HHS). Learn more about the show. Subscribe to healthcare FORsights™ to receive tailored healthcare sector insights directly to your inbox. Related content: 340B Program: Major Developments Through Early 2026 OB3: What It Means for Healthcare CMS Rule Signals Shift in Medicaid State-Directed Payments Medicaid Community Engagement: How Hospitals Can Prepare Payor &amp; Hospital Price Transparency Data-Driven Strategy New Cost Report Requirement: Reporting MA Negotiated Rates Resources: Opportunity Listing - Rural Hospital Provider Assistance Program Technical Assistance Webinar - Rural Hospital Provider Assistance Program Download our Healthcare Market Point of View: Achieving Health. Download our Mindsets 2026 Healthcare Executive Leadership Report. Questions? Contact us. Connect on LinkedIn: Healthcare Practice at Forvis Mazars Chad Mulvany Shawn Stack Victoria Duffel

Washington Watch: 340B Rebate Model Returns, Price Transparency Enforcement

Achieving Health

On today's episode of Achieving Health, we've got the latest policy and legislative updates from Washington, D.C. for the week of June 24th. Stay tuned. This is Achieving Health, a podcast from Forvis Mazars, where we delve into the topics that matter most to healthcare organizations across the continuum of care. Our goal is to help you navigate the dynamic healthcare landscape and achieve health at your organization.

Welcome to Achieving Health. I'm Chad Mulvaney. And I'm Sean Stack. Thank you for joining us. Let's get started with today's Washington Watch. These updates reflect information as of June 19th, 2026, and are subject to change. As far as our agenda is concerned, HRSA is advancing the 340B Rebate Model through a series of regulatory steps, including a request for information, a pre-rule submission to OMB,

and a new information collection request aimed at addressing legal deficiencies that invalidated the original rebate model. Based on an information collection request HRSA recently released, the revised model is expected to broaden the scope to include drugs under Medicare price negotiation in both 2026 and 27, increasing exposure for covered entities and introducing significant operational compliance and data management challenges.

Also, from HFMA, the One Big Beautiful Bill Act is expected to raise the risk of credit rating downgrades for not-for-profit hospitals by reducing Medicaid coverage and ACA marketplace enrollment, potentially lowering revenue over time. While larger systems may adapt, many providers must proactively improve efficiency, adjust services, and implement credible mitigation strategies to withstand prolonged financial pressure.

In the last few weeks, healthcare price transparency has been brought back into the spotlight, with the administration, HHS, and CMS turning up the heat, warning that hospitals not meeting their expectations around compliance and engagement, will face escalating penalties and heightened public scrutiny.

Washington Watch: 340B Rebate Model Returns, Price Transparency Enforcement

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Washington Watch: 340B Rebate Model Returns, Price Transparency Enforcement

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.